IRBM’s ADVENT GMP facility was recently mentioned in a Sunday Telegraph article covering the race to find a vaccine for COVID 19. The article talks about our collaboration with the Jenner Institute, Oxford University, who will produce the adenovirus-based vaccine…
Stopping the night time kissing bug: IRBM’s scientists recently published a Bioorganic & medicinal chemistry paper on a novel class of inhibitors for Chagas Disease, an infectious disease caused by the parasite Trypanosoma cruzi, spread by an insect commonly referred…
Manuel Daldin, Scientist - High Throughput Biology and Screening and Heidi Kingdon Jones, Global VP Business Development are attending the Biomarker conference in Manchester. Manuel will be presenting on the “development and validation of an assay to detect mutant huntingtin…
The Jenner Institute, Oxford University, UK and Advent Srl – an IRBM company, Pomezia,Italy - are continuing their long-standing history of collaboration, by announcing today a new agreement to develop a novel vaccine for coronavirus. The Jenner Institute at the…
Next week, IRBM’s Vice Presidents, Dan Conlon and Michele Luche will be attending the annual JP Morgan Healthcare Conference – the largest healthcare investment symposium in the industry. Get in touch to organise a meeting with Dan and Michele to…
We were delighted to author a recent Bioanalysis Zone article discussing the power of high-resolution mass spectrometry (HRMS) when investigating peptide-based modalities in drug discovery. In the article, Simone Esposito, Research Investigator in the DMPK group, explores the extensive applications of the technology for…
Our Global VP of Sales and Marketing, Heidi Kingdon Jones, is attending TIDES Europe: Oligonucleotide and Peptide Therapeutics in Amsterdam. Running from November 12-15, the event is Europe's primary forum for thought leaders in this growing field to network and…
From November 11-13, we will be attending BIO-Europe in Hamburg. Our Global VP of Sales and Marketing, Heidi Kingdon Jones, and VP of North American Business Development, Michele Luche, will be on hand to talk about our exceptional drug discovery…
From October 24-25, our Vice President of North American Business Development, Dan Conlon, is attending the Peptide Therapeutics Symposium at the Salk Institute in California. Now in its 14th year, the event unites key opinion leaders and eminent researchers in…
